| 1. |
Motzer RJ, Schmidinger M, Eto M, Suarez C, Figlin R, Liu Y, Perini R, Zhang Y, Heng DY:, LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy., Future Oncol, Future Oncol 19 (2): 113-121, 2023, 2023.01. |
| 2. |
Nishimura K, Shiota M, Eto M, Satoh T, Stroupe A, Seo C, Uzumcu A, Ledesma DA:, Conceptual assessment of HRQOL among Japanese non-metastatic castration-resistant prostate cancer (nmCRPC) patients., Cancer Med, Cancer Med 12 (2): 1762-1778, 2023, 2023.01. |
| 3. |
Kawano T, Inokuchi J, Eto M, Murata M, Kang JH:, Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer., Cancers (Basel), Cancers (Basel) 14 (21): 5425, 2022, 2022.11. |
| 4. |
Eto M, Lee JL, Chang YH, Gao S, Singh M, Gurney H:, Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region., Asia Pac J Clin Oncol, Asia Pac J Clin Oncol 18 (5): e191-e203, 2022, 2022.10. |
| 5. |
Shiota M, Akamatsu S, Tsukahara S, Nagakawa S, Matsumoto T, Eto M:, Androgen receptor mutations for precision medicine in prostate cancer., Endocr Relat Cancer, Endocr Relat Cancer 29 (10): R143-R155, 2022, 2022.08. |
| 6. |
Matsumoto T, Shiota M, Blas L, Eto M:, Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician's Perspective., Cancer Manag Res, 2022.08. |
| 7. |
Blas L, Shiota M, Eto M:, Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data., Cancers (Basel), Cancers (Basel) 14 (17): 4161, 2022, 2022.08. |
| 8. |
Kiyozawa D, Kohashi K, Takamatsu D, Iwasaki T, Shibata D, Tomonaga T, Tateishi Y, Eto M, Kinjo M, Nishiyama K, Taguchi K, Oshiro Y, Kuboyama Y, Furuya M, Oda Y:, Approach for reclassification of collecting duct carcinoma and comparative histopathological analysis with SMARCB1/INI1-deficient renal cell carcinoma and fumarate hydratase-deficient renal cell carcinoma., Hum Pathol, Hum Pathol 124: 36-44, 2022, 2022.06. |
| 9. |
Shiota M, Blas L, Eto M:, Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy., Cancers (Basel), Cancers (Basel) 14 (11): 2696, 2022, 2022.05. |
| 10. |
Kawano T, Inokuchi J, Eto M, Murata M, Kang JH:, Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials., Pharmaceutics, Pharmaceutics 13 (11): 1748, 2021, 2021.10. |
| 11. |
Kobayashi T, Takeuchi A, Nishiyama H, Eto M:, Current status and future perspectives of immunotherapy against urothelial and kidney cancer., Jpn J Clin Oncol, Jpn J Clin Oncol 51 (10): 1481-1492, 2021, 2021.10. |
| 12. |
Shiota M, Akamatsu S, Narita S, Terada N, Fujimoto N, Eto M:, Genetic Polymorphisms and Pharmacotherapy for Prostate Cancer., JMA J, JMA J 4 (2): 99-111, 2021, 2021.04. |
| 13. |
Inokuchi J, Yokomizo A, Nishiyama N, Kitamura H, Eto M, Nishiyama H, Tomita Y:, Perioperative therapies for urological cancers., Jpn J Clin Oncol, Jpn J Clin Oncol 50 (4): 357-367, 2020, 2020.04. |
| 14. |
Kato K, Takeuchi A, Akashi K, Eto M:, Cyclophosphamide-Induced Tolerance in Allogeneic Transplantation: From Basic Studies to Clinical Application., Front Immunol, Front Immunol 10: 3138, 2020, 2020.01. |
| 15. |
Shiota M, Fujimoto N, Kashiwagi E, Eto M:, The Role of Nuclear Receptors in Prostate Cancer., Cells, Cells 8 (6): 602, 2019, 2019.06. |
| 16. |
Inokuchi J, Eto M:, Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma., Cancer Manag Res, Cancer Manag Res 11: 4519-4528, 2019, 2019.05. |
| 17. |
Takeuchi A, Kato K, Akashi K, Eto M:, Cyclophosphamide-induced tolerance in kidney transplantation avoids long-term immunosuppressive therapy., Int J Urol, Int J Urol 25 (2): 112-120, 2018, 2018.02. |
